Back

Cangrelor use in ticagrelor-loaded ST-elevation myocardial infarction patients with high residual platelet reactivity: a randomized controlled trial.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Integrating insights: from biomarkers to therapeutics in the management of acute coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Adrien Lemaitre

University Hospital of Caen, Caen (France)

7 More presentations in this session

Presentation thumbnail
Increased circulating levels of standardized inflammatory and endothelial dysfunction biomarkers in patients with myocardial infarction with nonobstructive coronary arteries.
Doctor M. Espinosa Pascual (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Markers of coagulation and early coronary stent thrombosis
Doctor L. Galli (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
The potential impact of bisphosphonates on major adverse cardiovascular events: a study of 1,097,406 patients
Doctor K. Atieh (Dallas, US)
Abstract Slides Video
Presentation thumbnail
The sooner the better? What is the optimal timing for coronary angiography in high-risk non-ST-elevation acute coronary syndrome
Doctor C. Carvalho (Viana do Castelo, PT)
Abstract Slides Video
Presentation thumbnail
Mortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis
Doctor P. Lee (Bronx, US)
Abstract Slides Video

Access the full session

Session thumbnail
Integrating insights: from biomarkers to therapeutics in the management of acute coronary syndromes

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis
thumbnail
Congress Presentation
Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction
thumbnail
Congress Presentation
Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources